A randomized, placebo-controlled, phase 2 study of the efficacy and safety of droxidopa in patients with intradialytic hypotension

References

• Shimizu K, Kurosawa T, Sanjo T. Effect of hyperosmolality on vasopressin secretion in intradialytic hypotension: a mechanistic study. Am J Kidney Dis 2008;52:294–304.
   PubMed Web of Science ®Google Scholar
• Selby NM, McIntyre CW. The acute cardiac effects of dialysis. Semin Dial 2007;20:220–8.
   PubMed Web of Science ®Google Scholar
• Palmer BF, Henrich WL. Recent advances in the prevention and management of intradialytic hypotension. J Am Soc Nephrol 2008;19:8–11.
   PubMed Web of Science ®Google Scholar
• Laupacis A, Muirhead N, Keown P, Wong C. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. Nephron 1992;60:302–6.
   PubMed Web of Science ®Google Scholar
• Perazella MA. Pharmacologic options available to treat symptomatic intradialytic hypotension. Am J Kidney Dis 2001;38:S26–36.
   PubMed Web of Science ®Google Scholar
• Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004;66:1212–20.
   PubMed Web of Science ®Google Scholar
• Agarwal R. How can we prevent intradialytic hypotension? Curr Opin Nephrol Hypertens 2012;21:593–9.
   PubMed Web of Science ®Google Scholar
• Sherman RA. Intradialytic hypotension: an overview of recent, unresolved and overlooked issues. Semin Dial 2002;15:141–3.
   PubMed Web of Science ®Google Scholar
• Sulowicz W, Radziszewski A. Dialysis induced hypotension—a serious clinical problem in renal replacement therapy. Med Pregl 2007;60:14–20.
   PubMedGoogle Scholar
• Kaufmann H, Brannan T, Krakoff L, et al. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology 1988;38:951–6.
   PubMed Web of Science ®Google Scholar
• Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997;277:1046–51.
   PubMed Web of Science ®Google Scholar
• ProAmatine (midodrine hydrochloride) tablets [patient information leaflet]. Newport, Kentucky: Shire US, Inc; 2003.
   Google Scholar
• Akizawa T, Koshikawa S, Iida N, et al. Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients. Nephron 2002;90:384–90.
   PubMed Web of Science ®Google Scholar
• Iida N, Tsubakihara Y, Shirai D, et al. Treatment of dialysis-induced hypotension with L-threo-3,4-dihydroxyphenylserine. Nephrol Dial Transplant 1994;9:1130–5.
   PubMed Web of Science ®Google Scholar
• Kooman J, Basci A, Pizzarelli F, et al. EBPG guideline on haemodynamic instability. Nephrol Dial Transplant 2007;22:ii22–44.
   PubMed Web of Science ®Google Scholar
• Clinical Practice Guidelines for Hemodialysis Adequacy, Update 2006. New York, NY: National Kidney Foundation, Inc.; 2006. Available from http://www.kidney.org/professionals/KDOQI/guideline_upHD_PD_VA/index.htm. Accessed July 29, 2014.
   Google Scholar
• Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315–25.
   PubMed Web of Science ®Google Scholar
• Yang CY, Yang WC, Lin YP. Postdialysis blood pressure rise predicts long-term outcomes in chronic hemodialysis patients: a four-year prospective observational cohort study. BMC Nephrol 2012;13:12.
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 2003;108:724–8.
   PubMed Web of Science ®Google Scholar
• Cruz DN, Mahnensmith RL, Brickel HM, Perazella MA. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. Clin Nephrol 1998;50:101–7.
   PubMed Web of Science ®Google Scholar
• Cruz DN, Mahnensmith RL, Perazella MA. Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients? Am J Kidney Dis 1997;30:772–9.
   PubMed Web of Science ®Google Scholar
• Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S1–S290.
   PubMed Web of Science ®Google Scholar
• Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension. Kidney Int 2008;73:759–64.
   PubMed Web of Science ®Google Scholar
• Jindal K, Chan CT, Deziel C, Canadian Society of Nephrology Committee for Clinical Practice Guidelines. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006;17:S1–S27.
   PubMed Web of Science ®Google Scholar
• Takeda A, Toda T, Fujii T, et al. Can predialysis hypertension prevent intradialytic hypotension in hemodialysis patients? Nephron Clin Pract 2006;103:c137–43.
   PubMedGoogle Scholar
• Kayikcioglu M, Tumuklu M, Ozkahya M, et al. The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. Nephrol Dial Transplant 2009;24:956–62.
   PubMed Web of Science ®Google Scholar
• Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology 1999;53:2151–7.
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Holmes C, Kaufmann H, Freeman R. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res 2004;14:363–8.
   PubMed Web of Science ®Google Scholar
• Iida N, Koshikawa S, Akizawa T, et al. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients. Am J Nephrol 2002;22:338–46.
   PubMed Web of Science ®Google Scholar
• Kaufmann H. The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors. J Neural Transm Suppl 2006:477–84.
   PubMedGoogle Scholar
• Sun CY, Lee CC, Wu MS. Hypoglycemia in diabetic patients undergoing chronic hemodialysis. Ther Apher Dial 2009;13:95–102.
   PubMed Web of Science ®Google Scholar
• Gabrielli D, Krystal B, Katzarski K, et al. Improved intradialytic stability during haemodialysis with blood volume-controlled ultrafiltration. J Nephrol 2009;22:232–40.
   PubMed Web of Science ®Google Scholar
• Rocco MV, Burkart JM. Prevalence of missed treatments and early sign-offs in hemodialysis patients. J Am Soc Nephrol 1993;4:1178–83.
   PubMed Web of Science ®Google Scholar
• Sehgal AR, Leon J, Soinski JA. Barriers to adequate protein nutrition among hemodialysis patients. J Ren Nutr 1998;8:179–87.
   PubMedGoogle Scholar
• Zager PG, Nikolic J, Brown RH, et al. “U” curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998;54:561–9.
   PubMed Web of Science ®Google Scholar